Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Non-current Liabilities
All obligations due after more than one year.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $217K, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 0.3% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 117K | -74.9% |
| FY2023 | 2023-12-31 | 466K | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 155K | — |
Total Non-current Liabilities vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Total non-current liabilities amounts to 0.3% of total assets for UNCY, versus a peer median of 5.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $274.78M USD | +14.5% | +170.0% | 84.8% |
| Mar 2026 | $57.93M USD | +1117.0% | — | 54.9% | |
| Mar 2026 | $18.37M USD | +182.6% | +120.7% | 39.6% | |
| Mar 2026 | $9.1M USD | -37.0% | -23.1% | 5.1% | |
| Mar 2026 | $3.74M USD | +49714.6% | — | 1.6% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.12M CAD | -72.8% | +9.2% | 13.5% |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.26M USD | -47.6% | -28.7% | 1.2% |
| Mar 2026 | $217K USD | — | — | 0.3% | |
| Mar 2026 | $146K USD | -30.5% | -52.4% | 0.1% | |
| Mar 2026 | $0 USD | -100.0% | -68.1% | 0.0% | |
| Peer median (excluding UNCY) | — | -30.5% | -23.1% | 5.1% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.